Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15418065 | 1.00 | REN (0.88) | REN | |
| SCHEMBL20548988 | 1.00 | REN (0.88) | REN | |
| SCHEMBL19512220 | 1.00 | REN (0.88) | REN | |
| SCHEMBL24294897 | 0.94 | REN (0.84) | REN | |
| Sitokiren SCHEMBL29492575 | 0.94 | REN (1.00) | REN | |
| Sitokiren SCHEMBL26960855 | 0.94 | REN (1.00) | REN | |
| Sitokiren SCHEMBL19512224 | 0.94 | REN (1.00) | REN | |
| Sitokiren SCHEMBL19512247 | 0.94 | REN (1.00) | REN | |
| Sitokiren SCHEMBL16471588 | 0.94 | REN (1.00) | REN | |
| Sitokiren SCHEMBL16471589 | 0.94 | REN (1.00) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398946-B1 | SALT OF MORPHOLINE DERIVATIVE AND CRYSTALLINE FORM THEREOF, AS WELL AS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE OF THE SAME | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | claimed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | claimed |
| EP-3398946-B1 | SALT OF MORPHOLINE DERIVATIVE AND CRYSTALLINE FORM THEREOF, AS WELL AS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE OF THE SAME | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-10519150-B2 | Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-12-31 | — | — | US | disclosed |
| US-20190016718-A1 | SALTS OF MORPHOLINE DERIVATIVE, CRYSTAL FORMS THEREOF, PROCESSES FOR PRODUCING THE SAME, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND USE THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3398946-A1 | SALT OF MORPHOLINE DERIVATIVE AND CRYSTALLINE FORM THEREOF, AS WELL AS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE OF THE SAME | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519150-B2 | Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof | MDH1, MDH2, ME1 | REN 171/4885 |
| US-20190016718-A1 | SALTS OF MORPHOLINE DERIVATIVE, CRYSTAL FORMS THEREOF, PROCESSES FOR PRODUCING THE SAME, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND USE THEREOF | MDH1, MDH2, ME1 | REN 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.